We are live on ! Find out more
QNRX

Quoin Pharmaceuticals

22 hedge funds and large institutions have $7.82M invested in Quoin Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

40.75% more ownership

Funds ownership: 100.46%141.21% (+41%)

16% more funds holding

Funds holding: 1922 (+3)

36% less capital invested

Capital invested by funds: $12.2M → $7.82M (-$4.34M)

Holders
22
Holders Change
+3
Holders Change %
+15.79%
% of All Funds
0.27%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
6
Increased
7
Reduced
4
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
IC
1
Ikarian Capital
Texas
$1.4M
DIG
2
Dauntless Investment Group
New Hampshire
$1.3M +$1.78M +196,592 New
SC
3
SummitTX Capital
Texas
$662K +$322K +35,505 +55%
VCIM
4
Velan Capital Investment Management
Georgia
$560K +$769K +84,849 New
WP
5
Woodline Partners
California
$525K
Millennium Management
6
Millennium Management
New York
$503K +$13K +1,430 +2%
Aberdeen Group
7
Aberdeen Group
United Kingdom
$495K
SCM
8
Soleus Capital Management
Connecticut
$480K +$432K +47,730 +191%
CC
9
Centiva Capital
New York
$396K +$434K +47,947 +398%
BFM
10
Boothbay Fund Management
New York
$395K
SCM
11
Stonepine Capital Management
Oregon
$353K -$224K -24,729 -32%
ACM
12
AIGH Capital Management
Maryland
$337K +$15.2K +1,677 +3%
Citadel Advisors
13
Citadel Advisors
Florida
$215K +$295K +32,519 New
BC
14
Birchview Capital
Vermont
$132K +$181K +20,000 New
Morgan Stanley
15
Morgan Stanley
New York
$26.4K +$9.06K +1,000 +33%
UBS Group
16
UBS Group
Switzerland
$16.6K +$22.6K +2,495 +14,676%
GI
17
GAMMA Investing
California
$11.4K -$3.3K -364 -17%
RhumbLine Advisers
18
RhumbLine Advisers
Massachusetts
$10K -$1.31K -145 -9%
Barclays
19
Barclays
United Kingdom
$8.58K +$11.8K +1,300 New
SS
20
SBI Securities
Japan
$13 -$2.22K -245 -99%
HNB
21
Huntington National Bank
Ohio
$6
ACM
22
ADAR1 Capital Management
Texas
-$840K -58,230 Closed
RCAP
23
Resolute Capital Asset Partners
Colorado
-$433K -30,000 Closed
SAM
24
Simplify Asset Management
Nevada
-$252K -17,448 Closed
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
+$100 +11 New

QNRX Hedge Fund Activity: Q1 2026 in Review

22 of the 8,131 institutional investors tracked by Wall St. Rank reported a position in Quoin Pharmaceuticals (QNRX) for Q1 2026, worth a combined $7.82M — down 36% from $12.2M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new QNRX positions and 3 closed out — a net gain of 3 holders — while 7 added to existing stakes and 4 trimmed.

The largest buyer was Dauntless Investment Group, opening a new position worth an estimated $1.78M. The largest seller was ADAR1 Capital Management, exiting entirely with an estimated $840K sold.

  • 22 institutional investors held Quoin Pharmaceuticals (QNRX) as of Q1 2026, up from 19 in Q4 2025.
  • Funds reported $7.82M of Quoin Pharmaceuticals stock for Q1 2026, down 36% quarter-over-quarter.
  • 6 funds opened new Quoin Pharmaceuticals positions in Q1 2026 and 3 closed out, a net change of +3 holders.
  • The largest Quoin Pharmaceuticals buyer in Q1 2026 was Dauntless Investment Group, an estimated $1.78M added.
  • The largest Quoin Pharmaceuticals seller in Q1 2026 was ADAR1 Capital Management, an estimated $840K sold.

Based on aggregated 13F filings for Q1 2026.